
Invitris
Invitris is a YC Winter 2023 (W23) company. Based in Munich, BY, Germany. Team of 6.
About Invitris
Summary
Invitris builds a cell-free biomanufacturing platform that converts a digital protein sequence into a physical drug substance in four to eight hours. It targets the gap between AI-designed drugs and the production infrastructure needed to deliver them, replacing slow, batch-oriented cell-based manufacturing with a single-step, autonomous process that works across a wide range of protein classes. A lead application is producing patient-specific bacteriophages to treat antibiotic-resistant infections.
Business model
A fee per manufacturing program run through the platform.
Go-to-market
Invitris sells manufacturing programs to pharmaceutical and biotech developers working on individualized biologics, engaging them directly to run sequences through its platform under GMP-compliant, aseptic conditions.
From the Y Combinator listing
Creating new protein-based drugs at scale
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- Munich, BY, Germany
- 6
- Active
- Early
Founders (2)
- Kilian Vogele
- Patrick Grossmann
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works